Meet ANZ's best Medical Affairs professionals
Thirteen medical affairs professionals, some representing their teams, have been recognised for their outstanding contribution to the industry across Australia and New Zealand
Thirteen medical affairs professionals, some representing their teams, have been recognised for their outstanding contribution to the industry across Australia and New Zealand
Relocating to Australia from London, this global value and access high-flyer has been snapped up by J&J for a senior leadership position
This pharma has set an ambitious goal to establish a portfolio of more than 100 biosimilars by 2040, up substantially from the 13 it currently markets
After 12 years, this well-known leader who has worked tirelessly for equity in cancer care is standing down with a successor already named
The MAPA Medical Affairs Summit is preparing attendees for the way AI will change their roles, underlining how important it is that they exert influence independent of their job title
An industry-wide upheaval is coming to pharma with a monster patent cliff fall to hit in the next four years and even one of the world's newest blockbusters is not safe
The new resource is a living, curated repository bringing the growing evidence base around the medical affairs function together in one place - and its free
A company has announced its sponsorship of the Poweroos, saying the partnership reflects a broader commitment to supporting people living with rare and neuromuscular conditions
When it comes to favourite pharmas, one company is a clear standout according to this patient cohort which says industry's overall corporate reputation has improved... except in one crucial area
Minister deftly sidesteps questions about growing speculation he is the Labor Party's "leader-in-waiting" when Anthony Albanese's time as PM comes to an end
Rare Cancers Australia is calling for a raft of reforms, including reducing the median time from TGA approval of a medicine to PBS listing from 639 days to just 60
Australian States and Territories have been ranked on how well they support families who are getting treatment for cancer, and only one passed muster.
The BMS Patient & Parliament Summit will be held in Canberra today with urgent action needed for patients who fear they won't survive the wait for treatment
New figures released by the Department of Health shows more than one million women have accessed newly PBS listed medicines since March 2025
A survey including Australian doctors has revealed which HCPs have the highest trust in AI tools - and which specialties are not AI fans as the TGA investigates regulations in the space
High-flyer has been promoted to Country Lead, taking responsibility for heading the company's innovative medicines business in Australia
A previously prescription-only drug has hit the shelves as a pharmacy drug, with the hope it will increase awareness of the ability to treat symptoms
Jobs have been cut following a recent field force review with changes made to ensure the company's customer coverage model reflects an evolving market
The agenda for the November PBAC meeting has been updated with one company rejected in July making quick work of trying again
A new asthma treatment set to be considered for PBS funding at the PBAC's intracycle meeting this month has been approved for use in Australia
Two senior pharma executives - one a former Aussie GM - have called out perfect work-life balance as an unrealistic expectation placed on the industry
Despite the overall trend of tech dominance in the US, two pharmaceutical companies have broken into TIME’s Top 10 list of America’s Best Companies for 2026.
Medicines Australia has outlined an ambitious plan for the Government to double its spending on innovative medicines
Stepping up from a Business Unit Director role, this executive has packed her bags and made the move to Bulgaria, to take on the position of General Manager at a Big Pharma
Companies have been urged to apply the "PUB Test" to upcoming initiatives designed to engage HCPs - before they go to market - otherwise they risk missing the mark